Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of a recombinant bivalent norovirus vaccine in healthy participants aged 6 months to 59 years
CTR20211467Phase 2Active
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant bivalent norovirus vaccine in acute gastroenteritis, sponsored by Lanzhou Institute of Biological Products Co., Ltd.. Started Jun 2021; status: active.
02
Drugs
recombinant bivalent norovirus vaccine
03
Conditions
acute gastroenteritis
Beyond the preview
Go deeper on CTR20211467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211467.